We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ITT Q2 Earnings & Revenues Beat Estimates, Decrease Y/Y
Read MoreHide Full Article
ITT Inc. (ITT - Free Report) reported better-than-expected results in second-quarter 2020, wherein both earnings and revenues surpassed the Zacks Consensus Estimate.
In the reported quarter, the company pulled off an earnings surprise of 58.3%. Quarterly adjusted earnings were 57 cents per share, outpacing the Zacks Consensus Estimate of 36 cents. However, the bottom line declined 38.7% from the year-ago figure.
Revenues of $514.7 million were down 29% year over year. However, the top line surpassed the consensus mark of $507 million by 1.5%. Also, revenues fell 27.6% on an organic basis.
Segmental Breakup
Second-quarter revenues of Industrial Process were $193.3 million, down 16.9% year over year. Organic sales declined 16.6%, owing to lower revenues from pump projects and weakness across the short-cycle business.
Quarterly revenues of Motion Technologies declined 37.3% year over year to $199.3 million. Organic sales decreased 34.7% in the quarter mainly due to lower Friction sales on account of soft demand, owing to the coronavirus outbreak.
Connect & Control Technologies generated $122.9 million revenues, down 27.8% year over year. Organic sales dipped 29.3%, owing to weakness across aerospace and defense end markets amid the coronavirus outbreak.
Cost of sales in the second quarter was $351.1 million, down 28.1% year over year. Sales and marketing expenses were $35.7 million compared with $42.7 million in the year-ago quarter.
Gross profit margin was 31.8%, down 40 basis points.
In the quarter, income tax benefits were $28.1 million compared with income tax expenses of $19.3 million in the year-ago quarter.
Balance Sheet/Cash Flow
Exiting the second quarter, ITT had cash and cash equivalents of $819.1 million, up from $612.1 million as of Dec 31, 2019. Short-term debt and current maturities of long-term debt were $247.5 million compared with $86.5 million at the end of 2019.
In the first six months of 2020, the company generated $203.1 million in cash from operating activities, higher than $101.1 million recorded in the year-ago comparable period. Capital expenditure totaled $34.3 million, declining from $45.8 million spent in the year-ago comparable period.
2020 Guidance
ITT expects the pandemic to continue impacting its businesses throughout 2020. It believes that the reduction in demand for automotive and aerospace components will continue to hurt its top-line performance. In addition, volatile oil and gas market, and weak capital expenditure might affect its performance.
On uncertainties, regarding the impacts of the coronavirus outbreak on financial and operating results, ITT has not provided its earnings and revenues guidance for 2020.
Zacks Rank & Stocks to Consider
The company currently carries a Zacks Rank #3 (Hold).
AGCO delivered an earnings surprise of 409.54%, on average, in the trailing four quarters.
Avery Dennison delivered an earnings surprise of 7.70%, on average, in the trailing four quarters.
Berry Global delivered an earnings surprise of 16.34%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
ITT Q2 Earnings & Revenues Beat Estimates, Decrease Y/Y
ITT Inc. (ITT - Free Report) reported better-than-expected results in second-quarter 2020, wherein both earnings and revenues surpassed the Zacks Consensus Estimate.
In the reported quarter, the company pulled off an earnings surprise of 58.3%. Quarterly adjusted earnings were 57 cents per share, outpacing the Zacks Consensus Estimate of 36 cents. However, the bottom line declined 38.7% from the year-ago figure.
Revenues of $514.7 million were down 29% year over year. However, the top line surpassed the consensus mark of $507 million by 1.5%. Also, revenues fell 27.6% on an organic basis.
Segmental Breakup
Second-quarter revenues of Industrial Process were $193.3 million, down 16.9% year over year. Organic sales declined 16.6%, owing to lower revenues from pump projects and weakness across the short-cycle business.
Quarterly revenues of Motion Technologies declined 37.3% year over year to $199.3 million. Organic sales decreased 34.7% in the quarter mainly due to lower Friction sales on account of soft demand, owing to the coronavirus outbreak.
Connect & Control Technologies generated $122.9 million revenues, down 27.8% year over year. Organic sales dipped 29.3%, owing to weakness across aerospace and defense end markets amid the coronavirus outbreak.
ITT Inc. Price, Consensus and EPS Surprise
ITT Inc. price-consensus-eps-surprise-chart | ITT Inc. Quote
Costs/Margins
Cost of sales in the second quarter was $351.1 million, down 28.1% year over year. Sales and marketing expenses were $35.7 million compared with $42.7 million in the year-ago quarter.
Gross profit margin was 31.8%, down 40 basis points.
In the quarter, income tax benefits were $28.1 million compared with income tax expenses of $19.3 million in the year-ago quarter.
Balance Sheet/Cash Flow
Exiting the second quarter, ITT had cash and cash equivalents of $819.1 million, up from $612.1 million as of Dec 31, 2019. Short-term debt and current maturities of long-term debt were $247.5 million compared with $86.5 million at the end of 2019.
In the first six months of 2020, the company generated $203.1 million in cash from operating activities, higher than $101.1 million recorded in the year-ago comparable period. Capital expenditure totaled $34.3 million, declining from $45.8 million spent in the year-ago comparable period.
2020 Guidance
ITT expects the pandemic to continue impacting its businesses throughout 2020. It believes that the reduction in demand for automotive and aerospace components will continue to hurt its top-line performance. In addition, volatile oil and gas market, and weak capital expenditure might affect its performance.
On uncertainties, regarding the impacts of the coronavirus outbreak on financial and operating results, ITT has not provided its earnings and revenues guidance for 2020.
Zacks Rank & Stocks to Consider
The company currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks are AGCO Corporation (AGCO - Free Report) , Avery Dennison Corporation (AVY - Free Report) and Berry Global Group, Inc. (BERY - Free Report) . While AGCO sports a Zacks Rank #1 (Strong Buy), Avery Dennison and Berry Global carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AGCO delivered an earnings surprise of 409.54%, on average, in the trailing four quarters.
Avery Dennison delivered an earnings surprise of 7.70%, on average, in the trailing four quarters.
Berry Global delivered an earnings surprise of 16.34%, on average, in the trailing four quarters.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>